ClinicalTrials.gg

Program

Sinovac PCV13

Also written as “Sinovac PCV13 lot 1”, “Sinovac PCV13 lot 2” and “Sinovac PCV13 lot 3”.

Its studies are mostly in Pneumococcal Infections, led by Sinovac Biotech.

Furthest: phase 3, since Sep 26, 20244 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech43 open or runningphase 3since Sep 26, 2024Dec 13, 2023Mar 2027phase 3 · NCT07832500

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2023First study: phase 1 study in Pneumococcal InfectionsFirst studyNCT06183216 · 140 enrolled · China
  2. Sep 26, 2024Phase 3 study in Pneumococcal InfectionsNCT06617715 · 3,080 planned · China
  3. May 11, 2026Phase 3 study in Pneumococcal Infectious DiseasesNCT07593924 · 500 planned · Philippines
  4. Sep 16, 2026Phase 3 study in Pneumococcal Infectious DiseasesNCT07832500 · 1,125 planned · China

Ahead

  1. Mar 2027Primary completion: phase 3 study in Pneumococcal Infectious DiseasesNCT07832500
  2. Jul 2027Primary completion: phase 3 study in Pneumococcal Infectious DiseasesNCT07593924

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07832500Pneumococcal Infectious Diseases · China3Not yet recruitingMar 20271,125
NCT07593924Pneumococcal Infectious Diseases · Philippines3Not yet recruitingJul 2027500
NCT06617715Pneumococcal Infections · China3RecruitingMay 12, 20263,080
NCT06183216Pneumococcal Infections · China1CompletedMar 26, 2025140

How it is read

Names in the registry

  • “Sinovac PCV13”, 3 entries
  • “Sinovac PCV13 lot 1”, 1 entry
  • “Sinovac PCV13 lot 2”, 1 entry
  • “Sinovac PCV13 lot 3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.